Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of G-CSF Stimulated Bone Marrow from Pediatric Donors
NCT00118326Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2003
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgrastim in kidney cancer, leukemia, lymphoma and 3 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Safety and feasibility of filgrastim-mobilized bone marrow. Started Aug 2003; status: completed.
02
Drugs
filgrastim
03
Conditions
kidney cancerleukemialymphomamyelodysplastic syndrome (MDS)neuroblastoma
Beyond the preview
Go deeper on NCT00118326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118326.